Updated
Reviewed by Chandani Patel
Europe Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$759.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $604.0 Mn | — | — |
| 2025 (base) | $657.7 Mn | +$53.8 Mn | — |
| 2026 (forecast) | $716.2 Mn | +$58.5 Mn | +8.9% |
| 2027 (forecast) | $780.0 Mn | +$63.7 Mn | +18.6% |
| 2028 (forecast) | $849.4 Mn | +$69.4 Mn | +29.1% |
| 2029 (forecast) | $925.0 Mn | +$75.6 Mn | +40.6% |
| 2030 (forecast) | $1.01 Bn | +$82.3 Mn | +53.2% |
| 2031 (forecast) | $1.10 Bn | +$89.7 Mn | +66.8% |
| 2032 (forecast) | $1.19 Bn | +$97.6 Mn | +81.6% |
| 2033 (forecast) | $1.30 Bn | +$106.3 Mn | +97.8% |
| 2034 (forecast) | $1.42 Bn | +$115.8 Mn | +115.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.27 Bn
Canada
$238.1 Mn
Japan
$225.2 Mn
China
$224.6 Mn
Germany
$98.1 Mn
France
$92.2 Mn
Brazil
$87.5 Mn
UK
$82.5 Mn
Italy
$72.6 Mn
India
$67.4 Mn
Saudi Arabia
$61.2 Mn
Ecuador
$59.7 Mn
Spain
$52.6 Mn
Mexico
$52.1 Mn
Australia
$36.2 Mn
New Zealand
$33.0 Mn
Russia
$31.8 Mn
South Africa
$20.7 Mn
UAE
$15.7 Mn
Egypt
$8.8 Mn
Philippines
$7.7 Mn
Malaysia
$5.7 Mn
Hong Kong
$5.1 Mn
Thailand
$3.8 Mn
Singapore
$3.7 Mn
Kenya
$2.2 Mn
| Market size, 2025 | $657.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.42 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, application and end user (see all) |
| Key players | Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.
Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.
The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 2 shared keywords
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Pharmaceuticals · Europe
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Digital Health · Europe
Healthcare Services · Europe